IAVI 333d ago

How was a global team able to launch a ring vaccination trial in just four days during an #Ebola outbreak? On Jan. 30, Uganda confirmed its sixth disease outbreak due to Sudan virus (SUDV), an orthoebolavirus that causes a severe and often fatal viral hemorrhagic fever. IAVI, the World Health Organization, Ugandan health officials, and other partners quickly mobilized to begin administering IAVI’s investigational SUDV vaccine candidate* by Feb. 3. The outbreak was declared over on Apr. 26. We sat down with Swati Gupta, IAVI’s VP and head of emerging infectious diseases and epidemiology, to discuss this blueprint for a successful outbreak response. Watch this IAVI Impact video to learn more about the global health security risks posed by SUDV, and how a vaccine is urgently needed to help prevent future outbreaks. IAVI Impact is a video series spotlighting how IAVI’s work is addressing urgent and unmet #globalhealth needs. === Fast facts about the outbreak: https://www.iavi.org/features/fast-facts-about-iavis-contributions-to-the-2025-sudan-virus-disease-outbreak-in-uganda/ *In 2022, Merck, known as MSD outside the United States and Canada, produced and donated to IAVI vials of rVSV∆G-SEBOV-GP candidate vaccine from existing investigational drug substance to supplement IAVI’s ongoing SUDV vaccine development program. IAVI now acts as developer and regulatory sponsor and is responsible for all aspects of future development of rVSV∆G-SEBOV-GP. #vaccineswork #pandemicpreparedness #healthforall #infectiousdiseases